Market Overview - The Personalized Nutrition Market was valued at USD 15.80 billion in 2025 and is projected to reach USD 60.92 billion by 2035, growing at a CAGR of 15.04% from 2026 to 2035 [1][7]. Market Drivers - Rising awareness of preventive healthcare, increasing lifestyle-related chronic diseases, and growing demand for customized wellness solutions are key factors driving the market [2]. - Consumers are increasingly seeking individualized diet plans, DNA-based programs, nutrigenomics testing, and AI-powered supplement recommendations [2]. Regional Insights - The United States is the market leader, with an estimated worth of USD 5.85 billion in 2025 and a projected CAGR of 15.11%, reaching USD 22.27 billion by 2035 [4]. - North America held over 38.64% of the market share in 2025, attributed to high consumer literacy around preventive health and the advantages of DNA-based dietary programs [15]. - Asia Pacific is the fastest-growing segment with a CAGR of 17.43%, driven by increasing awareness of precision dietary solutions and government health initiatives [14]. Market Segmentation - By Product: Dietary supplements & nutraceuticals accounted for approximately 42.36% of revenue in 2025, while the digitized DNA segment is expected to grow at nearly 17.82% CAGR [9]. - By End-User: The direct-to-consumer segment held about 53.28% of the market share and is projected to grow at a CAGR of around 15.63% [10]. - By Measurement Method: Active measurement dominated with a 61.47% share in 2025, driven by real-time monitoring capabilities [11]. - By Form: Capsules held a leading share of 34.19% in 2025, while the powder segment is projected to grow at the highest CAGR of 16.54% [12]. - By Application: Standard supplements accounted for 48.73% of the market, with the disease-based segment expected to expand at a CAGR of 16.91% [13]. Major Players - Key players in the market include Nestlé S.A., Amway Corporation, Herbalife Nutrition Ltd., and Abbott Laboratories [16][20]. - Recent developments include Nestlé's expansion of its personalized nutrition portfolio with AI-powered tools and Amway's launch of a DNA-linked supplement platform [20].

Core Insights - Royal Philips has initiated the SHERPA research consortium to conduct seven clinical studies focused on AI- and robotics-assisted workflows for minimally invasive treatments of brain aneurysms and liver tumors, addressing the challenges posed by staff shortages and the complexity of procedures [2][5][8]. Group 1: Project Overview - The SHERPA project is a four-year initiative with a total budget of EUR 21.5 million, co-funded by the European Union Innovative Health Initiative and industry partners, involving 16 partners from seven European countries [3][6]. - The project aims to develop AI-powered technologies for imaging, data visualization, procedure planning, clinical decision support, and patient pathway orchestration to ease the workload of interventional (neuro)radiologists [2][8]. Group 2: Clinical Studies and Technologies - The clinical studies will focus on AI-driven aneurysm detection, risk prediction, and precise treatment planning for brain aneurysms, as well as advanced imaging and robotic-assisted biopsy technologies for liver and lung tumors [10][13]. - During the first year, the consortium successfully developed AI algorithms for identifying brain aneurysms needing treatment and optimizing patient selection for liver tumor ablation, along with robotic technology to enhance procedure precision [9][10]. Group 3: Industry Context and Challenges - The World Health Organization predicts a shortage of 600,000 physicians in the European Union by 2030, with significant shortages in interventional radiology, highlighting the need for innovative solutions to improve patient access and relieve pressure on healthcare professionals [5][6]. - The demand for image-guided, minimally invasive procedures is outpacing the growth of the specialized workforce, necessitating the integration of technology to support interventional radiologists in managing complex tasks while maintaining patient care [4][5].

Core Insights - BlackLine, Inc. is hosting the BeyondTheBlack event in Paris on June 25, 2026, aimed at finance and accounting leaders to discuss finance transformation and best practices [1] - The event will feature keynote sessions from BlackLine executives and focus on automation and intelligence in finance operations [1] - Attendees will engage in interactive sessions and networking opportunities, celebrating 25 years of BlackLine [1] Event Details - Date: June 25, 2026 - Time: 08:30 – 20:00 - Location: 28 George V, Paris 8 [1] Company Overview - BlackLine is a platform for the Office of the CFO, focusing on digital finance transformation through automation and intelligence [1] - The company serves over 4,400 customers across various industries, emphasizing accurate and efficient financial operations [1]

GREENWICH, Conn.--(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that Swedish investors can now trade global futures and options as well as access portfolio lending within their ISK (Investeringssparkonto) accounts, enabling broader international diversification and greater portfolio flexibility. Interactive Brokers announced that Swedish investors can now trade global futures and options as well as access portfolio lending within their ISK (Investeringsspar ...

Core Insights - Quell Therapeutics has shared interim top-line data from its LIBERATE Phase 1/2 trial, indicating promising results for its QEL-001 CAR-Treg therapy in liver transplant patients [1][3][10] - The company is initiating the QEL-005 CHILL clinical trial to explore a new CAR-Treg therapy targeting complex autoimmune diseases, building on insights from the LIBERATE trial [1][8] LIBERATE Trial Findings - The LIBERATE trial focuses on QEL-001, an anti-HLA-A2 CAR-Treg therapy, aimed at reducing immunosuppression in liver transplant patients [2][10] - Interim data shows QEL-001 is well tolerated, with no serious adverse events reported among the 9 patients dosed [6][7] - All patients in the study who were weaned off tacrolimus, a calcineurin inhibitor, maintained stability for at least 6 months without evidence of rejection [7] - QEL-001 demonstrated durable engraftment in the liver, remaining detectable for over a year post-dose, and showed a stable, suppressive Treg phenotype [7][10] Future Clinical Strategy - Based on the LIBERATE findings, Quell plans to prioritize the QEL-005 CHILL trial, which targets refractory rheumatoid arthritis and systemic sclerosis [8][13] - Early clinical data from the CHILL trial is expected in Q1 2027, indicating a focus on expanding the company's therapeutic pipeline [8][13] Company Overview - Quell Therapeutics is a leader in engineered T-regulatory cell therapies, utilizing its proprietary Foxp3 Phenotype Lock technology to develop treatments for immune-driven medical conditions [11][12] - The company is advancing multiple programs, including partnerships with AstraZeneca for Type 1 Diabetes and Inflammatory Bowel Disease [13]

Looking at what you've been writing over the last couple of days, it seems as if you you maybe think that markets aren't reacting quickly enough to the developments in the Middle East. In which assets do you see that most notably, Mark is not a stock story, is it oil. It's not so much the speed of reaction. It's the it's kind of the delayed attitude is very complacent.I think that over the weekend, what we saw was a game changing event. I'm always in favor of not being too knee jerk. Monday's price action d ...

Core Insights - uCloudlink Group Inc. unveiled its strategic roadmap at MWC 2026, focusing on unlocking significant market opportunities through global connectivity, IoT, and pet technology [1] Group 1: Strategic Growth Engines - The company introduced the eSIM Trio, targeting a multi-billion-dollar market of 4 billion smartphones with physical SIM slots, offering MVNOs a low-cost pathway to global scale [1] - uCloudlink launched the petpogo ecosystem, capitalizing on the $320 billion global pet market, enabling carriers to provide high-margin subscription services and proactive care [1] - The company is enhancing IoT capabilities with patented technologies, managing millions of devices with precision and enabling manufacturers to transition from selling products to operating global services [1] Group 2: Innovative Solutions - uCloudlink continues to lead in Mobile Broadband and LIFE segments with solutions like "Invisible Wi-Fi" and OmniFlex Pro, embedding connectivity into essential tools for users [1] - The MeowGo G50 Max is introduced as an AI-powered hub for a seamless travel experience, integrating various network types [1]

Core Viewpoint - Toyota's increased bid for Toyota Industries is seen as a win for Elliott Investment Management, but it does not fully address governance concerns, particularly regarding minority shareholders [1]. Group 1: Bid Details - Toyota raised its offer for Toyota Industries to 20,600 yen ($131) per share, valuing the bid at $30 billion, which was a response to pressure from Elliott Investment Management [1]. - The initial offer was 16,300 yen per share, which faced backlash from minority shareholders for being underpriced and lacking transparency [1]. - Elliott had previously rejected a bid of 18,800 yen per share, stating the shares were worth approximately 26,134 yen each [1]. Group 2: Governance Concerns - Despite the increased offer, analysts argue that the bid remains unfair to minority shareholders, as it does not resolve underlying governance issues [1]. - The classification of group companies as independent minority shareholders has raised questions about the fairness of the deal, as it lowers the voting threshold needed for approval [1]. - Concerns about inadequate financial disclosure and transparency over expected synergies were highlighted by the Asian Corporate Governance Association [1]. Group 3: Shareholder Dynamics - For the bid to succeed, 42.01% of shareholders classified as minority owners must accept the offer, excluding Toyota Motor's 24.66% stake [1]. - Chairman Akio Toyoda is set to increase his stake in Toyota Industries from 0.05% to 0.5%, tightening his control over the company [1]. - Some investors view the final offer as inadequate given the asset quality, but they may have little choice but to accept due to Elliott's influence [1].

Core Insights - Circle Internet Group's stock surged 31% following a strong fourth-quarter earnings report, despite earlier declines due to Bitcoin's performance and concerns over AI disruption [1][4] Financial Performance - Circle reported a 77% increase in revenue, reaching $770.2 million, surpassing analyst expectations of $745 million [4] - Adjusted earnings per share were $0.43, significantly exceeding estimates of $0.25 [4] - Revenue less distribution costs grew by 136% to $309 million, indicating strong operational performance [6] - Adjusted EBITDA increased by 412% to $167 million, showcasing substantial profitability growth [6] USDC and Market Growth - The circulation of USDC rose by 72% to $75.3 billion, with on-chain transactions growing by 247% to $11.9 billion [5] - The euro stablecoin also experienced significant growth, with circulation up 284% to 310 million euros [5] - Circle is benefiting from the growth of prediction markets like Polymarket, which utilize USDC [5] Future Outlook - Circle provided guidance for a 40% compound annual growth rate in USDC circulation through 2026, along with projected other revenue of $150 million to $170 million [9] - The launch of the new product Arc and conditional approval for a national trust bank are expected to enhance USDC's infrastructure and market acceptance [6][9]

Information regarding factors that could cause differences in actual results are available in today's press release and presentation and in Brink's and NCR Atleos' SEC filings. The information presented and discussed on the call is representative of today only. Brink's and NCR Atleos assume no obligation to update any forward- looking statements. The call is copyrighted and may not be used without written permission from Brink's and NCR Atleos. I will now turn it over to your host, Jesse Jenkins, Vice Presi ...